- Home
- BFRG vs SABS Comparison
BFRG vs SABS Comparison
Compare BFRG & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BFRG
- SABS
- Stock Information
- Founded
- BFRG 2017
- SABS 2014
- Country
- BFRG United States
- SABS United States
- Employees
- BFRG N/A
- SABS N/A
- Industry
- BFRG Retail: Computer Software & Peripheral Equipment
- SABS Biotechnology: Pharmaceutical Preparations
- Sector
- BFRG Technology
- SABS Health Care
- Exchange
- BFRG Nasdaq
- SABS Nasdaq
- Market Cap
- BFRG 16.4M
- SABS 15.8M
- IPO Year
- BFRG 2023
- SABS N/A
- Fundamental
- Price
- BFRG $1.61
- SABS $1.78
- Analyst Decision
- BFRG
- SABS Strong Buy
- Analyst Count
- BFRG 0
- SABS 5
- Target Price
- BFRG N/A
- SABS $11.80
- AVG Volume (30 Days)
- BFRG 145.0K
- SABS 18.6K
- Earning Date
- BFRG 08-06-2025
- SABS 08-07-2025
- Dividend Yield
- BFRG N/A
- SABS N/A
- EPS Growth
- BFRG N/A
- SABS N/A
- EPS
- BFRG N/A
- SABS N/A
- Revenue
- BFRG N/A
- SABS $377,835.00
- Revenue This Year
- BFRG N/A
- SABS N/A
- Revenue Next Year
- BFRG N/A
- SABS N/A
- P/E Ratio
- BFRG N/A
- SABS N/A
- Revenue Growth
- BFRG N/A
- SABS N/A
- 52 Week Low
- BFRG $1.23
- SABS $1.00
- 52 Week High
- BFRG $4.84
- SABS $5.01
- Technical
- Relative Strength Index (RSI)
- BFRG 44.03
- SABS 49.33
- Support Level
- BFRG $1.53
- SABS $1.60
- Resistance Level
- BFRG $1.67
- SABS $1.87
- Average True Range (ATR)
- BFRG 0.12
- SABS 0.11
- MACD
- BFRG -0.01
- SABS -0.01
- Stochastic Oscillator
- BFRG 21.28
- SABS 62.07
About BFRG Bullfrog AI Holdings Inc.
Bullfrog AI Holdings Inc is a clinical-phase Biotechnology company using machine learning to advance medicine and improve human health. It uses artificial intelligence and machine learning to advance medicines for both internal and external projects. Its platform technology, named, bfLEAP, is an analytical AI/ML platform that is able to surmount the challenges of scalability and flexibility currently hindering researchers and clinicians by providing a more precise1, multi-dimensional understanding of its data.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.